The Belgian Hematology Society (BHS), with the support of an unrestricted grant from Gilead Sciences and Kite, a Gilead company, has the pleasure to announce one grant to support research in the field of cellular therapies in hematological disease.
PROJECT SUBMISSION IS OPEN UNTIL Friday, 05 January 2024, midnight (extended deadline)!
Consult the GILEAD Award flyer
Researchers working in hematology are invited to submit their project and apply for the Gilead Cell Therapy Grants. All information on rules and regulations are available on the homepage , as is the application form.
The jury will select one winning project based on their innovative character, which will be awarded with EUR 25.000. The award ceremony will take place at the 39th BHS General Annual Meeting, February 2-3, 2024. Discover the past GILEAD AWARD winners down below!
We are looking forward to receiving outstanding projects that can advance the outcomes of hematological diseases through cellular therapies.
Sincerely,
Prof. Marc André, BHS President
PARTICIPATION REQUIREMENTS "GILEAD AWARD" 2024
Who can apply?
- Any researcher working on cellular therapies in hematological malignancies can apply.
Candidates working at a pharmaceutical company are excluded.
Which projects are eligible?
- The topic of research is related to transnational research within the field of cellular therapies in hematology. Innovative research on autologous or allogeneic stem cell transplant is also considered in scope.
Application requirements?
- Description of the research project including costs and time frame (max. 2 pages) - Example project submission GILEAD award 2024.docx
- Letter of support by a promoter from the department where the research will be performed (max. 1 page)
- Motivational letter (max. 1 page)
- List of publications (if applicable)
- CV
GILEAD Award
A monetary grant of EUR 25.000 will be awarded to the winner. The results of the selection will be announced during the 2024 General Annual Meeting of the BHS. This award has been made possible with an unrestricted grant from Gilead Sciences Belgium.
Only submission through the online tool is possible. Submissions sent by e-mail will not be considered.
Past Winners
2023
|
Winners
|
Projects
|
|
Gils Roex, Universiteit Antwerpen
|
Computer-Aided Design of optimized Chimeric Antigen Receptors for hematological malignancies
|
|
Fabio Andreozzi, Institut Jules Bordet
|
Impact of genetic and immune alterations on Anti-BCMA CAR T-cells treatment in heavily pre-treated multiple myeloma patients
|
2022
| Winners | Projects |
|
Inge Govaerts, UZ Leuven/KU Leuven
|
In-depth investigation of CAR T-cell behaviour to predict complications and outcome |
|
Virginie Chapelle, Cliniques universitaires Saint-Luc
|
Immunomonitoring during CAR-T cell therapy project : Interest of molecular biology and flow cytometry |
2021
| Winner | Project |
|
Prognosis and immuno-therapeutical role of circulating miRNAs in acute myeloid leukaemia (AML) allogeneic transplantation and cellular immunotherapy treatment optimisation |
|
Antigen-specific Non-signaling CARs as Hemato-Oncological Remedy (ANCHOR project) |